This Levaquin crap ruined Karen's future. Levofloxacin (Levaquin), Ciprofloxacin (Cipro), Moxifloxacin (Avelox), Norfloxacin (Noroxin), Ofloxacin (Floxin), Gemifloxacin (Factive) and Finafloxacin (Xtoro) should be taken off the market, and the FDA knows it! Levaquin made it so she could not walk from the tendinitis that it caused.__
It is my conjecture that this class of antibiotics are damaging the spinal Dura, what contains the spinal fluid, so that the treatments for her CSF Leaks did not work. There is ZERO study on this FQ drug/Dura connection.
I will be at the first ever Intracranial Hypotension Symposium this fall to discuss this with the worlds leading CSF Leak doctors.
Karen's medical records
Karen's medical records from 2003 when she was given Levaquin. I'm posting them in the hopes they will help someone.
Karen spent a year crawling because of Levaquin
Karen spent a year crawling around the house on this construction, skate board like thing so her ankles would heal:
FDA updates warnings for fluoroquinolone antibiotics Limits use for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections
For Immediate Release July 26, 2016
Release: The U.S. Food and Drug Administration today approved safety labeling changes for a class of antibiotics, called fluoroquinolones, to enhance warnings about their association with disabling and potentially permanent side effects and to limit their use in patients with less serious bacterial infections.
“Fluoroquinolones have risks and benefits that should be considered very carefully,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “It’s important that both health care providers and patients are aware of both the risks and benefits of fluoroquinolones and make an informed decision about their use.”
Fluoroquinolones are antibiotics that kill or stop the growth of bacteria. While these drugs are effective in treating serious bacterial infections, an FDA safety review found that both oral and injectable fluroquinolones are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system. These side effects can occur hours to weeks after exposure to fluoroquinolones and may potentially be permanent.
Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections, the FDA has determined that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options. For some serious bacterial infections, including anthrax, plague and bacterial pneumonia among others, the benefits of fluoroquinolones outweigh the risks and it is appropriate for them to remain available as a therapeutic option.
FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive). The labeling changes include an updated Boxed Warning and revisions to the Warnings and Precautions section of the label about the risk of disabling and potentially irreversible adverse reactions that can occur together. The label also contains new limitation-of-use statements to reserve fluoroquinolones for patients who do not have other available treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections. The patient Medication Guide that is required to be given to the patient with each fluoroquinolone prescription describes the safety issues associated with these medicines.
The FDA first added a Boxed Warning to fluoroquinolones in July 2008 for the increased risk of tendinitis and tendon rupture. In February 2011, the risk of worsening symptoms for those with myasthenia gravis was added to the Boxed Warning. In August 2013, the agency required updates to the labels to describe the potential for irreversible peripheral neuropathy (serious nerve damage).
In November 2015, an FDA Advisory Committee discussed the risks and benefits of fluoroquinolones for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections based on new safety information. The new information focused on two or more side effects occurring at the same time and causing the potential for irreversible impairment. The advisory committee concluded that the serious risks associated with the use of fluoroquinolones for these types of uncomplicated infections generally outweighed the benefits for patients with other treatment options.
Today’s action also follows a May 12, 2016, drug safety communication advising that fluoroquinolones should be reserved for these conditions only when there are no other options available due to potentially permanent, disabling side effects occurring together. The drug safety communication also announced the required labeling updates to reflect this new safety information.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Our Win at the FDA hearing on Fluoroquinolone Antibiotics. Links to FDA's 617 page FQAD report and the hearing videos
Please see: Our Win at the FDA hearing on Fluoroquinolone Antibiotics for details and videos of the hearing at the FDA on November 5th 2015.
FDA Hearing meeting brief and the 617 page PDF report where the the FDA identified a syndrome associated with fluoroquinolone toxicity—one that “floxies” have been pushing for recognition of for years. It is called Fluoroquinolone Associated Disability (FQAD). – see: Our Win at the FDA hearing on Fluoroquinolone Antibiotics for details.
My TV Interview
http://www.newsnet5.com/news/local-news/investigations/levaquin-fda-fails-to-disclose-additional-serious-side-effects-of-antibiotic-linked-to-deaths is my Cleveland/Akron TV interview. 3,000 dead. 200,000 injured by these drugs per the FDA. That is estimated to be only one-percent of the real numbers!
The 23 names of Fluoroquinolones
|Nalidixic acid||NegGam, Wintomylon|
|Ciprofloxacin||Cipro, Cipro XR, Ciprobay, Ciproxin|
|Nadifloxacin||Acuatim, Nadoxin, Nadixa|
|Norfloxacin||Lexinor, Noroxin, Quinabic, Janacin|
|Ofloxacin||Floxin, Oxaldin, Tarivid|
Sadly new ones are being added all of the time. Five of the older generations were already pulled from the market due to the dangers they presented.
Ten Pages of Warnings for Levaquin
How many doctors have actually read the TEN PAGES of warnings in this 67 page document about Levaquin?
These people should be in jail
These people should be in jail for the rest of their lives!:
There is a new drug, Otezla (Apremilast), to treat psoriatic arthritis out. There have been reports that it works the same way as the above drugs, and has been attacking tendons. Not something I'd personally be taking after seeing what the drugs did to Karen.
FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolones
[8-15-2013] The U.S. Food and Drug Administration (FDA) has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones (see Table for a list) may occur soon after these drugs are taken and may be permanent.
The risk of peripheral neuropathy occurs only with fluoroquinolones that are taken by mouth or by injection. Approved fluoroquinolone drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive). The topical formulations of fluoroquinolones, applied to the ears or eyes, are not known to be associated with this risk.
If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped, and the patient should be switched to another, non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk. Peripheral neuropathy is a nerve disorder occurring in the arms or legs. Symptoms include pain, burning, tingling, numbness, weakness, or a change in sensation to light touch, pain or temperature, or the sense of body position. It can occur at any time during treatment with fluoroquinolones and can last for months to years after the drug is stopped or be permanent. Patients using fluoroquinolones who develop any symptoms of peripheral neuropathy should tell their health care professionals right away.
FDA will continue to evaluate the safety of drugs in the fluoroquinolone class and will communicate with the public again if additional information becomes available.
“…Commonly used FQs include levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin) and gemifloxacin (Factive).
For many people, the concept of being “floxed” is difficult to comprehend. “The reaction is mostly disbelief,” says Girard. “They have been taking antibiotics their whole life and never had anything like that. Or they have taken Cipro and they have arthritis or depression but don’t understand it could be from the Cipro. But the reaction is mostly disbelief - until it happens to you.”
Fluoroquinolones, or more accurately their precursors, were developed as a chemotherapy drug. When it was discovered that the compound could actually kill bacteria, they were reformulated and marketed as antibiotics. However, they are far from penicillin.
Simply put, fluoroquinolones work by entering the bacteria’s DNA and preventing it from reproducing. However, they do not work only on bacterial DNA. They actually penetrate all the cells in the body. It’s believed that the tendons rupture because the FQs confuse the DNA, and the cells literally get mixed up.
“Tendons will be rebuilding wrong, and rebuilding wrong until one day you overextend them and they snap. People get it in their shoulder, rotator cuff, hands, wrist,” adds Girard. … ” – Mark Girard; Fluoroquinolone Toxicity Group
Other fluoroquinolones related publications and sites. Not one is supportive of this crap!:
George Lesher discovered Quinolone's in 1962. – Laughing Gas, Viagra, and Lipitor: The Human Stories behind the Drugs We Use By Jie Jack Li.
Facebook Support Groups
Facebook Support Groups: [There are actually 87 of them now, these are the main ones of the ones that I follow]
News Coverage [There have now been over 150 main stream media stories]:
“A few popular antibiotics affect DNA, similar to some chemotherapy agents. If you’re sensitive to them, you could pay a neurological price that causes sudden and serious neuropathy and degrees of brain damage. The Food and Drug Administration is concerned about drugs in the fluoroquinolone class, and these already have a black box warning for an increased risk of tendon ruptures. But I’m telling you that more reports have come in with accusations of neurological damage.” - Suzy Cohen, RPh
Next, a Health Unit report about a medical mystery, and the questions it’s raising about the drug-monitoring system. It involves a class of antibiotic drugs that some people say are making them very ill. – Judy Woodruff
Are Dangerous Antibiotics Causing Chronic Illness? by Lisa Bloomquist. Lisa hosts The Floxie Hope Podcast, also via iTunes, from Floxie Hope.
The Fluoroquinolone Toxicity Solution is Your Path to Recovery eBook updated for 2014.
Doctors with positive reviews for FQ Syndrome (informally called "FQ Toxicity") Please note that I do not maintain this list. Please read the list via the link and do not save, re-post or re-distribute, because the list can change frequently. For any questions regarding the list there is an email address listed on it. Courtesy of My Quin Story.
Drugwatch.com advocates for people to make a stand against prescription drugs that have harmful side effects and medical devices that cause damage. We do this by providing accurate, comprehensive information about these commonly used drugs and devices and by answering questions raised by people who contact us.
Our mission is to help our users evaluate if they have a legal case because of life-changing side effects or complications that were caused by a device maker or a drug company. We are sponsored by The Peterson Firm, a Washington, D.C., law firm, and we use the legal team at The Peterson Firm to educate these users about their circumstances. If a user expresses interest in speaking with a lawyer about bringing a legal case, a Patient Advocate may suggest a law firm to work with The Peterson Firm on the case. If a user retains the firms to handle his or her case, both firms will work on a contingency fee basis, with no costs or fees charged unless a recovery is made. Your Patient Advocate can explain the process in more detail.